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Abstract
Introduction: Leptin (LEP) and its receptor (LEPR) participate in the immunological response during infection. LEP
serum levels rise during sepsis. In patients with peritonitis, an insufficient elevation in serum LEP is associated with
an increased risk of death. As gene variants of LEP and LEPR have been associated with diverse pathologic
conditions, we explored the association of genetic polymorphisms of LEP or LEPR with death in patients with
secondary peritonitis.
Methods: A case control study was undertaken. LEP Gene -2548G > A and the LEPR Gene 223A > G polymorphism
were determined in 74 patients. The odds ratio of genotype and allele distribution in survival (control) versus death
(case) among patients was calculated. Serum LEP, interleukin (IL)-6, tumour necrosis factor alpha, C-reactive protein
(C-RP), IL-10 and IL-13 levels were analyzed in 34 patients.
Results: There were significant differences in genotype and allele distribution between survivors and non-survivors
for -2548G > A and 223A > G polymorphisms. The presence of the mutant allele A, in -2548, had an odds ratio of
4.64 (95% CI 1.22, 17.67) with significance (P = 0.017) in the risk of death. The presence of mutant allele G, in 223,
had an odds ratio of 3.57 (95% CI 1.06, 12.01) with significance in the risk of death (P=0.033). The presence of
allele A in the -2548 polymorphism was associated with differences in serum LEP (P=0.013), and IL-10 (P=
0.0001). The presence of allele G in 223 polymorphism was likewise correlated with differences in serum LEP (P <
0001), C-RP (P=0.033), and IL-10 (P=0.043).
Conclusions: The polymorphisms studied are associated with death in patients with peritonitis of non-
appendicular origin. This association is stronger than many known risk-factors related to peritonitis severity, and is
independent of body mass. The physiopathologic mechanism is possibly related to an insufficient increase in the
elevation of serum LEP levels, and is unrelated to body mass.
Introduction
Leptin (LEP) is a cytokine-like hormone that is primarily
synthesized and secreted by white adipose tissue. As a
hormone it has important functions in the regulation of
body weight, reproduction, immune functions, bone for-
mation and growth [1]. The biological activities of LEP
on target tissues are carried out through selective bind-
ing to a specific receptor. Leptin receptors (LEPR) form
homodimers that, in general, act by signaling via the
Janus kinases to regulate multiple events in target tis-
sues [2].
LEP and LEPR participate in the immunological
response during infection. LEP displays both pro- and
anti-inflammatory properties. It appears necessary for
the induction of interleukin (IL)-6 and tumour necrosis
factor alpha (TNF-a) after a lipopolysaccharide (LPS)
challenge, while at the same time it provides protection
against LPS- or TNFa-induced lethality [3,4]. In
humans, LEP levels are higher during sepsis [5-7]. In
surgically treated patients with peritonitis, an insufficient
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threefold-increase in the risk of death (sensitivity 94.4,
specificity 50%) [8].
Gene variants of LEP and LEPR have been associated
with obesity, non-Hodgkin’s lymphoma, non-insulin-
dependent diabetes mellitus, and essential hypertension
[1,9-12]. The purpose of this study was to explore the
association of genetic polymorphisms of LEP or LEPR
with an unfavourable outcome (death) in patients with
non-appendicular secondary peritonitis.
In an attempt to explain the low specificity of the
above mentioned LEP threshold, we hypothesized that
LEP and LEPR polymorphisms cause problems with
ligand-receptor binding, contributing to an unfavourable
outcome.
A positive association between LEP or LEPR poly-
morphisms and outcome; serum TNF-a,I L - 6( p r o -
inflammatory cytokines), IL-10 and IL-13 (anti-inflam-
matory cytokines), C-RP (acute phase protein), and LEP,
illustrating the overall acute phase response, would give
us an insight into the causes of the unfavourable
outcome.
Materials and methods
Patients
Eligible patients were ≥18 years old, with surgically con-
firmed secondary peritonitis, defined as a polymicrobial
infection of the peritoneum occurring as a consequence
of traumatic, infectious, ulcerative, obstructive or neo-
plastic pathology [13]. All were admitted to the Depart-
ment of General Surgery of the Hospital General de
Durango (Mexico). Excluded were patients with any
condition causing immune-depression, current treat-
ment with an immune-suppressive drug, and peritonitis
of appendicular origin. Appendicular peritonitis was
excluded because it generally has a favourable outcome
[14,15]. The case-group (non-survivors) included
patients that died after 24 h and within the 30-day post-
operative period. The control-group (survivors) was
comprised of those who survived the 30-day follow-up.
The Ethics Committee at the Hospital General de Dur-
ango (SSD) approved the study. Signed informed con-
sent was obtained from each patient.
The 74 patients recruited consisted of all consecutively
eligible patients. The sample was prospective. The first of
the patients also participated in a published study, and
the last 40 participated exclusively in this protocol [8].
The severity of peritonitis was determined using the
Mannheim Peritonitis Index (MPI). The score takes in
to account eight adverse factors: age > 50 years (5
points), female gender (5 points), multiple organ failure
(MOF) (7 points), neoplasia (4 points), > 24 h of evolu-
tion (4 points), non-colonic origin (4 points), generalized
peritonitis (6 points), with purulent (6 points) or
fecaloid (12 points) character. The MPI classifies sever-
ity in intervals: grade I (< 21 points), grade II (21 to 29
points), and grade III (> 29 points). It is a simple scoring
system, widely used, and is specific to peritonitis. With
this index, the grade-response relation between severity
of peritonitis and the concentration of key regulatory
serum cytokines has been demonstrated [16].
To assess the patients’ nutritional status, the Body
Mass Index (BMI) was used. Each individual was classi-
fied as follows: underweight (< 18.5 kg/m
2), normal
(18.5 to 24.9 kg/m
2), grade I overweight (25.0 to 29.9
kg/m
2), obese or grade 2 overweight (30.0 to 39.9 kg/
m
2), grade 3 overweight or morbid obese (> 40 kg/m
2)
[17].
In accordance with accepted practice principals, the
attending physician determined the treatment in each
case: correcting fluid and electrolyte deficiencies with
parenteral fluids; physiologic organ system support; sur-
gical treatment (source control, peritoneal lavage and
drainage) during open exploratory laparotomy along
with broad-spectrum antibiotic therapy [18,19].
Procedures
DNA extraction and LEP, LEPR genotyping
DNA was extracted from leukocytes using the DTAB/
CTAB method previously described [20]. Gene amplifi-
cation was performed by the conventional polymorph-
ism chain reaction (PCR) using the following primers:
for the LEP gene: forward 5’TTTCCTGTAATTT
TCCCGTGAG-3’ and reverse 5’AAAGCAAAGACAGG-
CATAAAAA-3’. Amplification of a 242 bp fragment
ensued under the following reaction conditions: initial
denaturing at 95°C for five minutes and 30 amplification
cycles of 94°C, 58.5°C and 72°C for one minute and a
final extension at 72°C for five minutes. For the LEPR
gene, we used the following primers: forward 5’AAACT-
CAACGACACTCTCCT-3’ and reverse 5’TGAACTGA-
CATTAGAGGTGAC-3’.T h i sg a v er i s et oap r o d u c to f
80 bp using the following amplification conditions: 94°C
× 2 minutes of initial denaturing, followed by 32 cycles
of 94°C for 1 minute, 50°C for 45 sec and 72°C for 30
sec, with a final extension of 7 minutes. After PCR all
products were stored at 4°C.
For the restriction fragment length polymorphism
(RFLPs), these PCR products were digested with restric-
tion enzymes, using CofI Promega
® (Madison, WI. USA)
1.0 U per 15 μL of the product of PCR was incubated at
37°C for 60 minutes for the -2548G > A polymorphism
in the LEP gene, generating a restriction pattern of 61
bp and 181 bp when the cleavage site is present. On the
other hand the enzyme MspIS i g m a
® (Saint Louis, MO.
USA) 1.5 U per 15 μLo ft h ep r o d u c to fP C Rw a si n c u -
bated at 37°C for 60 minutes was used for polymorph-
ism 223A > G of the LEPR gene, which generates a
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RFLPs were visualized by means of 2% agarose gel elec-
trophoresis stained with ethidium bromide [20].
At o t a lo fS1 . 5Up e r1 5μLo ft h ep r o d u c to fP C R ,
incubated at 37°C for 60 minutes, was used for poly-
morphism 223A > G of the LEPR gene, which generates
a cleavage site that produces 22 bp and 58 bp fragments.
RFLPs were visualized by means of 2% agarose gel elec-
trophoresis stained with ethidium bromide [20].
Cytokine and C-Reactive protein analysis
Serum LEP, IL-6, TNF-a, C-RP, IL-10 and IL-13 levels
were available for the first 34 patients. The blood sam-
ples were taken 18 to 24 h into the postoperative period,
irrespective of the time of day. It is during this interval
that LEP increases to its maximum postoperative value
[21-23].
The samples were allowed to clot, and serum was
separated by centrifugation and cryopreserved at -40°C,
until the time of cytokine and C-RP determination.
Thirty-four samples were processed to determine: LEP
(ng/ml), TNF-a (pg/ml), interleukins 6, 10 and 13 (pg/
ml), and C-RP (μg/100 ml). Each analyte was evaluated
separately using standard ELISA methods: IL-6 and IL-
10 were determined with Quantikine
® HS (R&D Sys-
tems, Minneapolis, MN, USA), LEP, IL-13, and TNF-a
with Quantikine
® kits (R&D Systems). C-RP was deter-
mined with the AlerChek kit for C-RP (AlerCHEK™,
Portland, ME, USA).
Statistical analysis
For the sample size calculation we took into consideration
frequencies of 77.4% and 70.14% for polymorphisms
-2548G > A, and 223A > G respectively, in accordance
with Wang et al. in patients with morbid obesity and resis-
tance to insulin [24]. Therefore, an average prevalence of
75% was considered adequate to calculate our sample size,
with a variation up to a 10%. Using program EPIDAT (for-
mula n =Z
2 pq/d
2) we calculated a sample n =7 3 .
Categorical variables were reported as counts, percen-
tages and 95% CI, and continuous variables as means ±
SD, median and percentiles. For categorical variables,
the chi-square test was used to assess differences. For
continuous variables, a t-test and ANOVA were
employed. Odds ratios (OR) and confidence intervals
were calculated. P-values less than 0.05 indicated statis-
tical significance. Data were collected and analyzed
using the SPSS V. 15.0.1 (SPSS Inc. Chicago, IL, USA,
2006) and Epidat 3.1 (Xunta de Galicia/PHO, A Coruña,
Galicia, España, 2006) software.
Results
Study population
The case-control population comprised 74 adults (41
males and 33 females, mean age: 54.7 ± 21.1 years). The
non-survivors were 22 patients (10 males and 12
females, mean age: 68.5 ± 14.6 years). The survivors
were 52 patients (31 males and 21 females, mean age:
48.8 ± 20.8 years). The mean hospital stay for all
patients was 7.15 ± 5.73 days. A mean BMI of 24.75 ±
3.82, along with the low total proteins, albumin, and A/
G ratio (Table 1), suggest malnutrition. A low mean ery-
throcyte count, haemoglobin, and hematocrit coincide
with this appraisal. The mean MPI of the case-control
population was 23.12 ± 9.10 points. A high white blood
cell count, with bandemia, along with high total biliru-
bin and direct bilirubin (Table 1), reflect the severity of
the sepsis among the study subjects.
The sources of secondary peritonitis were the small
intestine 24.32% (n = 18), gallbladder and biliary tree
17.56% (n = 13), colon 16.21% (n = 12), stomach 16.21%
(n = 12), liver 13.51% (n = 10), uterus and fallopian
tubes 4.05% (n = 3), duodenum 4.05% (n = 3), pancreas
1.35% (n = 1), spleen 1.35% (n = 1), and retroperito-
neum 1.35% (n = 1).
Clinical characteristics
Comparing survivors and non-survivors, there was a dif-
ference in age (P = 0.0001), but there was neither a dif-
ference in sex-ratio (P = 0.3874), nor in hospital stay in
days (P = 0.828). With respect to BMI categories of
underweight (n =0vs.3 ) ,n o r m a l( 2 6vs. 11), grade I
overweight (20 vs. 6), and obese (6 vs. 2), there was no
difference (P = 0.052) between controls and cases. There
were differences in total proteins (P = 0.006), albumin
(P = 0.0001), and in the A/G ratio (P = 0.0001), between
survivors and non-survivors, and in MPI scores (P <
0.0001).
Comparing the MPI adverse factors between each
group (Table 2), a difference was found for age > 50
years (P = 0.0076), generalized peritonitis (P = 0.0483),
the presence of MOF (P < 0001), and coexisting neopla-
sia (P = 0.0007).
Comparison of genetic characteristics
The genotypic distribution of the alleles represented by
the polymorphism of the leptin gene at -2548 was in
Hardy-Weinberg equilibrium (P-value of two-tailed chi-
square 0.113807), while the genotype distribution of
polymorphism 223 was in disequilibrium (P-value of
two tailed chi-square 0.023312).
-2548 polymorphism
Analysis of the allele distribution in survival versus
death among patients with non-appendicular secondary
peritonitis (Table 3) showed a higher frequency of the A
allele among those with an unfavourable outcome (P =
0.002). Considering a dominant model, an odds ratio of
4.64 (95% CI 1.22, 17.67) with statistical significance (P
= 0.017) was found using contingency tables with A/A +
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versus G/G, and in the columns, survival versus death.
223 polymorphism
Analysis of the allele distribution (Table 3) in the con-
trols versus cases showed a non-significant trend toward
higher frequency of the G allele among non-survivors (P
= 0.011). Analyzing G/G + G/A, as an adverse factor
versus A/A, while comparing the outcome, survival ver-
sus death, showed a difference, (P = 0.033) with an
odds-ratio of 3.57 (95% CI 1.06, 12.01).
Association of genetic polymorphisms with clinical
characteristics
Other than death, with an odds-ratio of 4.6 (P =0 . 0 1 7 )f o r
-2548 polymorphism, and with an odds-ratio of 3.6 (P =
0.0334) for 223 polymorphism, no other clinical variable was
found associated with either genetic polymorphism (Table 4).
Cytokines
The presence of mutant allele A (21/34) with respect to
-2548 polymorphism was associated with differences in
serum LEP (P = 0.013), and IL-10 (P = 0.0001), com-
pared to the wild type allele G. The presence of mutant
allele G (22/34) with respect to 223 polymorphism
s h o w e dad i f f e r e n c ei ns e r u mLEP (P < 0001), C-RP (P
= 0.033), and IL-10 (P = 0.043), compared to the wild
type allele A. But, of the aforementioned P-values, only
serum LEP in the presence of the 223 polymorphism fell
in the 95% CI (Table 5).
If we compare the means of the study subjects with
cytokine levels (n = 34) with those without these mea-
surements (n = 40) there are no statistically significant
differences in age (P = 0.197), sex (0.483), BMI classifi-
cation (P = 0.607), the presence of -2548 polymorphism
(P = 0.472) or 223 polymorphism (P = 1.000). These
subsamples are equivalent, because all enrolled into the
study in the manner stated in the Methods section.
Discussion
T h ep o p u l a t i o nb a s eo ft h eH o s p i t a lG e n e r a ld eD u r -
ango, SSD is comprised mainly of underprivileged
patients that lack access to social security medical
Table 1 Mean laboratory findings in 74 patients with non appendicular secondary peritonitis
Study Mean Reference value 95% confidence interval
Erythrocytes 4.22 ± 1.11 × 10
6 4.5 to 6.0 male, 4.2 to 5.4 × 10
6 female (3.76, 4.68)
Hemoglobin 12.79 ± 3.47 g/dL 12 to 17 male, 11 to 15 g/dL female (11.36, 14.22)
Hematocrit 38.55 ± 10.31% 41 to 52 male, 38 to 46% female (34.29, 42, 81)
Neutrophils 61.76 ± 27.27% 50 to 70% (50.50, 73.02)
Bands 15.92 ± 15.94% 0 to 3% (9.34, 22.50)
Platelets 288, 543 ± 160, 829 plts. 150 to 350 × 10
3 (222, 156.05, 354, 929.95)
Total proteins 5.49 ± 1.11 g/dL 6.5 to 8.0 g/dL (5.23, 5.76)
Albumin 2.46 ± 0.77 g/dL 3.5 to 5.0 g/dL (2.28, 2.65)
Globulins 3.03 ± 0.63 g/dL 2.5 to 3.5 g/dL (2.88, 3.18)
A/G ratio 0.82 ± 0.27 1.3 to 2.5 (0.76, 0.89)
Total bilirubin 1.42 ± 1.8 g/dL up to 1.1 g/dL (1.00, 1.84)
Direct bilirubin 0.788 ± 1.66 g/dL up to 0.25 g/dL (0.40, 1.18)
Indirect bilirubin 0.645 ± 0.49 g/dL 0.1 to 0.5 g/dL (0.53, 0.76)
Table 2 Mannheim Peritonitis Index adverse factors present in the 74 patients with non-appendicular secondary
peritonitis
Characteristic Survivors (n (%)) Non-survivors (n (%)) Total (n (%)) P
Age > 50 years 26 (50) 19 (86.4) 45 (60.8) 0.0076
Female gender 21 (40.4) 12 (54.5) 33 (44.6) 0.3874
Generalized peritonitis 31 (60) 19 (86.4) 50 (67.6) 0.0483
Duration > 24 h 44 (85) 21 (95.5) 65 (87.8) 0.3603
Purulent/fecal character 26 (50) 17 (77.3) 43 (58, 1) 0.0554
Non-colonic origin 44 (85) 15 (68.2) 59 (79.7) 0.1967
Presence of organ failure 4 (7.7) 14 (63.6) 18 (24.3) < 0.0001
Malignant disease 1 (1.9) 7 (31.2) 8 (10.8) 0.0007
MPI I 2 (9.1) 38 (73.1) 40 (54.1) 0.0000
MPI II 8 (36.4) 8 (15.4) 16 (21.6) 0.0901
MPI III 12 (54.5) 6 (11.5) 18 (24.3) 0.0003
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observed. In a gross nutritional assessment, we expected
no differences between cases and controls. Although
there were significant differences between survivors and
non-survivors in total proteins, albumin and the A/G
ratio, there was no significant difference in BMI, making
both groups comparable.
The differences in MPI severity between survivors and
non-survivors was expected because the index is prog-
nostic, and as the score increases, so does the probabil-
ity of a poor outcome.
The lack of Hardy-Weinberg equilibrium in the LEPR
223 polymorphism may be due to a low recombination
rate, different to that present in LEP gene polymorphism
-2548, within the promoter region.
Based on previous studies related to LEP and LEPR
polymorphisms, differences in LEP levels, and physiolo-
gical consequences were expected. Due to the fact that
LEP gene polymorphism -2548 is located in the promo-
ter region, it is associated with a low expression of LEP,
Table 3 The genotype and allele distribution among
patients with non appendicular secondary peritonitis
-2548 polymorphism Survivors
(n (%))
Non-survivors
(n (%))
P
Genotypes 0.014
GG 22 (42.3) 3 (13.6)
GA 21 (40.4) 9 (40.9)
AA 9 (17.3) 10 (45.5)
Alleles 0.002
G 65 (62.5) 15 (34.1)
A 39 (37.5) 29 (65.9)
223 polymorphism
Genotypes 0.072
GG 11 (21.15) 9 (40.9)
GA 18 (34, 62) 9 (40.9)
AA 23 (44.23) 4 (18.2)
Alleles 0.011
G 40 (38.5) 27 (61.4)
A 64 (61.5) 17 (38.6)
Table 4 Relationship between polymorphisms and clinical variables studied in patients with non-appendicular
secondary peritonitis.
-2548 223
Variable Adverse factor/Non-
adverse
Carriers Non-
carriers
P OR (IC95) Carriers Non-
carriers
P OR (IC95)
Age > 50 years 33 12 0.1069 2.2 (0.83, 5.99) 32 13 0.0908 2.3 (0.87, 6.08)
≤50 years 16 13 15 14
Sex Female 23 10 0.5701 1.3 (0.50, 3.53) 20 13 0.6411 0.8 (0.31, 2.06)
Male 26 15 27 14
Organ failure Present 16 3 0.0544 3.6 (0.93, 13.66) 15 4 0.1050 2.7 (0.79, 9.19)
Absent 33 22 32 23
Malignancy Present 7 1 0.1777 4.0 (0.47, 34.49) 7 1 0.1356 4.6 (0.53, 39.17)
Absent 42 24 40 26
Time
elapsed
> 24 h 43 22 0.9757 1.0 (0.22, 4.29) 43 22 0.2048 2.4 (0.60, 10.02)
≤24 h 6 3 4 5
Origin Non colonic 37 22 0.2062 0.4 (0.11, 1.66) 35 24 0.1374 0.4 (0.09, 1.43)
Colonic 12 3 12 3
Extension Generalized 33 17 0.9547 1.0 (0.35, 2.72) 34 16 0.2472 1.8 (0.66, 4.88)
Localized 16 8 13 11
Exudates Fecal 6 0 0.1004 1.9 (0.70, 4.95) 5 1 0.0710 2.4 (0.92, 6.39)
Purulent 25 12 26 11
Clear 18 13 16 15
Survival Survivor 19 3 0.017 4.6 (1.22,
17.67)
18 4 0.0334 3.6 (1.06,
12.01)
Non-survivor 30 22 29 23
BMI Overweight/
obese
22 12 0.8001 0.9 (0.34, 2.32) 22 12 0.8443 1.1 (0.42, 2.85)
Normal/
underweight
27 13 25 15
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223 polymorphism, found in the exonic region, causes
problems with ligand-receptor binding [12]. Both recep-
tors have been related with obesity, non-Hodgkin’s lym-
phoma, non-insulin-dependent diabetes mellitus,
essential hypertension, and resistance to insulin [10,12].
Of the variables studied, the -2548 polymorphism
superseded all other variables recognized as adverse fac-
tors for an unfavourable outcome. In the case of the 223
polymorphism, only coexistent malignancy surpassed it
among the adverse factors studied (Table 4). It stands
out that, other than outcome, none of the variables stu-
died was found to be significantly associated to either
polymorphism. As far as we know, this is the first report
of the association between LEP and LEPR genetic poly-
morphisms and death, in any form of sepsis.
The LEPR gene 223A > G polymorphism is expected
to have an impact on the binding of the hormone to its
receptor. A change at the binding site may affect the
union between the ligand and its receptor, modifying
the intracellular signaling events, thereby influencing the
expected physiologic response. The low concentration of
LEP and a subsequent loss of its protective effects then
has an impact on survival, but the presence of the poly-
morphism may contribute to this problem, explaining
the low specificity of this biomarker, in accordance to a
carrier or non-carrier state.
The fact that the poor outcome of patients with -2548
and 223 polymorphisms appears to be due to lower
serum levels of LEP coincides with our previous report
of a high risk of death in patients with surgically con-
firmed secondary peritonitis with low serum LEP levels.
As suggested by these results, the threshold of 6.6 ng/ml
(confirmed in this sample) should be taken as a predic-
tive marker, as we stated in that publication [8]. LEP
increases T-helper cells-1 (Th1) and suppresses Th2
cytokine production, hence its rise in sepsis promotes
the host’s pro-inflammatory response against its aggres-
sors, and the lack of increase observed favours an anti-
inflammatory pattern with an unfavourable outcome
[25].
Bornstein reported an increase of LEP in sepsis, with
lower levels among non-survivors [26,27]. A recent
study found that serum LEP is a powerful biomarker
that helps to differentiate sepsis from the non-infectious
systemic inflammatory response syndrome in critically
ill patients [28]. These findings, along with the afore-
mentioned threshold, and our present results, underline
the relevance of LEP in sepsis [8].
As to the possible mechanisms by which an insuffi-
cient increase in LEP may relate to mortality and sys-
temic inflammation during sepsis, in a murine model,
Tschöp et al. suggest that LEP deficiency leads to
impaired bacterial clearance at the site of infection, and
LEP replacement improves the immune response and
reduces organ damage in sepsis. These authors suggest
that the protective effect of LEP in sepsis occurs
through CNS signalling that coordinates an appropriate
immune response [29,30]. Shapiro et al., in mouse endo-
toxemia and caecal ligation puncture models of sepsis,
confirmed a rise in LEP levels in sepsis. Nonetheless, in
their studies, exogenously administered LEP increased
mortality, resulting in up-regulation of inflammatory
mediators during endotoxemia and LEP-mediated
endothelial dysfunction [31]. An explanation for these
differences may be found in the manner in which each
Table 5 Relationship between polymorphisms and cytokine/acute phase reactant studied in patients with non-
appendicular secondary peritonitis.
-2548 223
Cytokine/Acute phase
reactant
Carriers
n =2 1
Non-carriers
n =1 3
P (IC95) Carriers
n =2 2
Non-carriers
n =1 2
P (IC95)
Leptin 4.59 ng/ml 8.32 ng/ml 0.013 -3.52, 11.04 2.53 ng/ml 12.39 ng/ml <
0.0001
3.176,
16.52
IL-6 8.35 pg/ml 9.10 pg/ml 0.684 -1.28, 2.76 8.82 pg/ml 8.27 pg/ml 0.130 -1.49, 2.61
TNF 21.80 pg/ml 21.75 pg/ml 0.483 -9.69, 9.79 23.06 pg/ml 19.43 pg/ml 0.598 -6.19, 13.45
CRP 160.39 μg/100
ml
150.52 μg/100
ml
0.756 -24.47,
44.21
165.58 μg/100
ml
140.18 μg/100
ml
0.033 -8.49, 59.29
IL-10 17.95 pg/ml 8.51 pg/ml 0.0001 -7.95, 26.83 13.87 pg/ml 15.21 pg/ml 0.043 -16.66,
19.34
IL-13 12.71 pg/ml 19.60 pg/ml 0.910 -4, 56,
18.34
17.55 pg/ml 11.30 pg/ml 0.337 -5.45, 17.95
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replacement with intra-peritoneal injection, intra-cere-
bro-ventricular or peripheral mini-pumps (subcuta-
neous), while Shapiro et al. used osmotic pumps
implanted into the abdominal cavity, which might not
be the best choice if the model of sepsis is peritoneal.
The conflicting literature on LEP and sepsis is related
t ot h et y p eo fp a t i e n ts t u d i e d ,t h es o u r c eo ft h es e p s i s ,
and time of sampling, which is related to the complex
dynamics of cytokines [32-34]. These factors must be
taken into account so as not to confuse conflicting
results with differences in methodology and the design,
which is chosen in relation to the purpose of the study.
A useful question to ask when reading papers related
with research on LEP may be: does this paper study LEP
role as a classic hormone in the regulation of body mass
or its paper as a cytokine in the systemic inflammatory
response?
The sum of these findings underlines the need to
further study the role of LEP in sepsis.
Even though the results of the association between
outcome and the polymorphism studied are significant,
in spite of limitations in size of the sample, further stu-
dies with a larger group may show associations with
clinical variables, cytokines or acute phase reactants not
seen here.
Conclusions
The -2548G > A LEP gene, and 223A > G LEPR gene
polymorphisms are associated with death in patients
with surgically confirmed secondary peritonitis of non-
appendicular origin. This association is stronger than
many known risk-factors related to peritonitis severity,
and is independent of BMI. The patho-physiological
mechanism is believed to be related to an insufficient
increase in the elevation of serum LEP levels during
sepsis.
Key messages
￿ LEP Gene -2548G > A, and the LEPR Gene 223A >
G polymorphisms increase the risk of death in sec-
ondary peritonitis with an odds ratio of 4.64 and
3.57, respectively.
￿ These polymorphisms are related with an insuffi-
cient increase of LEP serum levels in peritonitis.
￿ The threshold of 6.6 ng/ml in serum LEP levels is
confirmed as an outcome marker.
Abbreviations
BMI: Body Mass Index; C-RP: C-reactive protein; IL: interleukin; LEP: leptin;
LEPR: leptin receptor; LPS: lipopolysaccharide; MOF: multiple organ failure;
MPI: Mannheim Peritonitis Index; OR: Odds ratios; PCR: polymorphism chain
reaction; RFLPs: restriction fragment length polymorphism; SSD: Secretaría de
Salud de Durango; TNF-α: tumour necrosis factor alpha
Acknowledgements
The study was funded by the Universidad Juárez del Estado de Durango
Author details
1Instituto de Investigación Científica, Universidad Juárez del Estado de
Durango, Calle Constitución 404 sur, Durango, Dgo. C.P. 34, 000, México.
2Servicio de Cirugía, Hospital General de Durango (SSD), Calle 5 de Febrero
esq. con C. Norman Fuentes s/n, Durango, Dgo. C.P. 34, 000, México.
3Laboratorio de genómica aplicada, CIIDIR-IPN Unidad Durango, Calle Sigma
119, Durango, Dgo. C.P. 34, 220, México.
4Facultad de Medicina y Nutrición,
Universidad Juárez del Estado de Durango, Calle Constitución 404 sur,
Durango, Dgo. C.P. 34, 000, México.
Authors’ contributions
RB and JPS conceived and designed the study. JPS and GAL collected the
data. VL and GAL carried out the molecular genetic studies and
immunoassays. AT, VL and RB performed the statistical analysis and drafted
the manuscript. RB and VL wrote the paper. All authors read and approved
the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 22 April 2011 Revised: 31 August 2011
Accepted: 23 September 2011 Published: 23 September 2011
References
1. van der Lende T, Te Pas MF, Veerkamp RF, Liefers SC: Leptin gene
polymorphisms and their phenotypic associations. Vitam Horm 2005,
71:373-404.
2. Paracchini V, Pedotti P, Taioli E: Genetics of leptin and obesity. Am J
Epidemiol 2005, 162:101-114.
3. Halle M, Persson PB: Role of leptin and leptin receptor in inflammation.
Am J Physiol Regul Integr Comp Physiol 2003, 284:R760-762.
4. Waelput W, Brouckaert P, Broekaert D, Tavernier J: A role for leptin in the
systemic inflammatory response syndrome and in immune response, an
update. Curr Med Chem 2006, 13:465-475.
5. Arnalich F, López J, Codoceo R, Jiménez M, Madero R, Montiel C:
Relationship of plasma leptin to plasma cytokines and human survival in
sepsis and septic shock. J Infect Dis 1999, 180:908-911.
6. Maruna P, Gürlich R, Frasko R, Rosicka M: Ghrelin and leptin elevation in
postoperative intra-abdominal sepsis. Eur Surg Res 2005, 37:354-359.
7. Maruna P, Gürlich R, Frasko R, Haluzík M: Serum leptin levels in septic men
correlate well with C-reactive protein and TNF-alpha but not with BMI.
Physiol Res 2001, 50:589-594.
8. Bracho-Riquelme RL, Reyes-Romero MA, Pescador N, Flores-García AI: A
leptin serum concentration less than 10 ng/ml is a predictive marker of
outcome in patients with moderate to severe secondary peritonitis. Eur
Surg Res 2008, 41:238-244.
9. Riestra P, Garcia-Anguita A, Viturro E, Schoppen S, de Oya M, Garcés C:
Influence of the leptin G2548A polymorphism on leptin levels and
anthropometric measurements in healthy Spanish adolescents. Ann Hum
Genet 2010, 74:335-339.
10. Ben Ali S, Kallel A, Ftouhi B, Sediri Y, Feki M, Slimane H, Jemaa R,
Kaabachi N: The -2548G/A LEP polymorphism is associated with blood
pressure in Tunisian obese patients. Blood Press 2008, 17:278-283.
11. Willett EV, Skibola CF, Adamson P, Skibola DR, Morgan GJ, Smith MT,
Roman E: Non-Hodgkin’s lymphoma, obesity and energy homeostasis
polymorphisms. Br J Cancer 2005, 93:811-816.
12. Chiu KC, Chu A, Chuang LM, Saad MF: Association of leptin receptor
polymorphism with insulin resistance. Eur J Endocrinol 2004, 150:725-729.
13. Suarez ME: Infecciones intraabdominales: Peritonitis y abscesos. Medicrit
2004, 1:146-180.
14. Lansdown MR, Gray AJ, Treasure T, Layer GT: Appendicectomy: who
performs it, when and how? Ann R Coll Surg Engl 2006, 88:530-534.
15. Margenthaler JA, Longo WE, Virgo KS, Johnson FE, Oprian CA,
Henderson WG, Daley J, Khuri SF: Risk factors for adverse outcomes after
the surgical treatment of appendicitis in adults. Ann Surg 2003, 238:59-66.
16. Bracho-Riquelme RL, Reyes-Romero MA, Torres-Valenzuela A, Flores-
García AI: The grade-response relation between severity of peritonitis
Bracho-Riquelme et al. Critical Care 2011, 15:R227
http://ccforum.com/content/15/5/R227
Page 7 of 8and serum cytokine concentrations explains Mannheim Peritonitis Index
threshold. Surg Infect 2010, 11:379-386.
17. Expert Committee on Physical Status: Physical Status: the Use and
Interpretation of Anthropometry: Report of the WHO Expert Committee
Geneva: WHO; 1995.
18. Marshall JC, Innes M: Intensive care unit management of intra-abdominal
infection. Crit Care Med 2003, 31:2228-2237.
19. Malangoni MA: Contributions to the management of intraabdominal
infections. Am J Surg 2005, 190:255-259.
20. Gustincich S, Manfidetti G, Del Sal G, Schneider C, Carninci P: A fast
method for high-quality genomic DNA extraction from whole human
blood. Biotechniques 1991, 11:298-300, 302.
21. Maruna P, Gürlich R, Frasko R: Dynamics of leptin plasma levels after
abdominal surgical procedures. Rozhl Chir 2001, 80:299-303.
22. Maruna P, Gürlich R, Frasko R: Leptin–a new acute phase reactant. Vnitr
Lek 2001, 47:478-483.
23. Kaska M, Zivný P: Serum leptin levels in the perioperative period in
surgery patients. Rozhl Chir 2002, 81:22-24.
24. Wang TN, Huang MC, Chang WT, Ko AM, Tsai EM, Liu CS, Lee CH, Ko YC: G-
2548A polymorphism of the leptin gene is correlated with extreme
obesity in Taiwanese aborigines. Obesity (Silver Spring) 2006, 14:183-187.
25. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI: Leptin
modulates the T-cell immune response and reverses starvation-induced
immunosuppression. Nature 1998, 394:897-901.
26. Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negrão AB, Gold P,
Chrousos GP: Plasma leptin levels are increased in survivors of acute
sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion.
J Clin Endocrinol Metab 1998, 83:280-283.
27. Torpy DJ, Bornstein SR, Chrousos GP: Leptin and interleukin-6 in sepsis.
Horm Metab Res 1998, 30:726-729.
28. Yousef AA, Amr YM, Suliman GA: The diagnostic value of serum leptin
monitoring and its correlation with tumor necrosis factor-alpha in
critically ill patients. Crit Care 2010, 14:R33.
29. Tschöp J, Nogueiras R, Haas-Lockie S, Kasten KR, Castañeda TR, Huber N,
Guanciale K, Perez-Tilve D, Habegger K, Ottaway N, Woods SC, Oldfield B,
Clarke I, Chua S Jr, Farooqi IS, O’Rahilly S, Caldwell CC, Tschöp MH: CNS
leptin action modulates immune response and survival in sepsis. J
Neurosci 2010, 30:6036-6047.
30. Tschöp J, Dattilo JR, Prakash PS, Kasten KR, Tschöp MH, Caldwell CC: The
leptin system: a potential target for sepsis induced immune
suppression. Endocr Metab Immune Disord Drug Targets 2010, 10:336-347.
31. Shapiro NI, Khankin EV, Van Meurs M, Shih SC, Lu S, Yano M, Castro PR,
Maratos-Flier E, Parikh SM, Karumanchi SA, Yano K: Leptin exacerbates
sepsis-mediated morbidity and mortality. J Immunol 2010, 185:517-524.
32. Jeevanandam M, Begay CK, Petersen SR: Plasma leptin levels in trauma
patients: effect of adjuvant recombinant human growth hormone in
intravenously fed multiple trauma patients. JPEN J Parenter Enteral Nutr
1998, 22:340-346.
33. Quasim T, McMillan DC, Wallace AM, Kinsella J: The relationship between
leptin concentrations, the systemic inflammatory response and illness
severity in surgical patients admitted to ITU. Clin Nutr 2004, 23:233-238.
34. Langouche L, Vander Perre S, Frystyk J, Flyvbjerg A, Hansen TK, Van den
Berghe G: Adiponectin, retinol-binding protein 4, and leptin in
protracted critical illness of pulmonary origin. Crit Care 2009, 13:R112.
doi:10.1186/cc10467
Cite this article as: Bracho-Riquelme et al.: Leptin and leptin receptor
polymorphisms are associated with poor outcome (death) in patients
with non-appendicular secondary peritonitis. Critical Care 2011 15:R227. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bracho-Riquelme et al. Critical Care 2011, 15:R227
http://ccforum.com/content/15/5/R227
Page 8 of 8